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Abstract 
Aims: Atrial fibrillation (AF) and frailty are common, and the prevalence is expected to rise 
further. We aimed to investigate the prevalence of frailty and the ability of a frailty index (FI) 
to predict unplanned hospitalizations, stroke, bleeding and death in patients with AF. 
Methods and results: Patients with known AF were enrolled in a prospective cohort study in 
Switzerland. Information on medical history, lifestyle-factors and clinical measurements were 
obtained. The primary outcome was unplanned hospitalization; secondary outcomes were all-
cause mortality, bleeding and stroke. The FI was measured using a cumulative deficit 
approach, constructed according to previously published criteria and divided into three groups 
(non-frail, pre-frail, frail). The association between frailty and outcomes was assessed using 
multivariable adjusted Cox regression models. Of the 2369 included patients, prevalence of 
pre-frailty and frailty was 60.7% and 10.6%, respectively. Pre-frailty and frailty were 
associated with a higher risk of unplanned hospitalizations (adjusted hazard ratio [aHR] 1.82; 
95% confidence interval [CI], 1.49-2.22, p<0.001; and aHR 3.59; 95%CI 2.78-4.63, p<0.001), 
all-cause mortality (aHR 5.07; 95%CI 2.43-10.59, p<0.001; and aHR 16.72; 95%CI 7.75-
36.05, p<0.001), and bleeding (aHR 1.53; 95%CI 1.11-2.13, p=0.01; and aHR 2.46; 95%CI 
1.61-3.77, p<0.001). Frailty, but not pre-frailty was associated with a higher risk of stroke 
(aHR 3.29; 95%CI 1.29-8.39, p=0.01). 
Conclusion: Over two thirds of patients with AF are pre-frail or frail. These patients have a 
high risk for unplanned hospitalizations and other adverse events. These findings emphasize 
the need to carefully evaluate these patients. However, whether screening for pre-frailty and 
frailty and targeted prevention strategies improve outcomes needs to be shown in future 
studies. 
Keywords: Atrial fibrillation, elderly, frailty, hospitalization, mortality 
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Introduction 
 Frailty is a common condition in geriatric patients, characterized by a reduced 
biological reserve and high vulnerability to adverse outcomes including death.1 Depending on 
the assessment tool and the population studied, the prevalence of frailty in patients with 
cardiovascular disease (CVD) was estimated from 10% to 60%.2  
 Atrial fibrillation (AF) is associated with substantial comorbidity, such as heart failure, 
or stroke, which by itself could contribute to frailty and disability in this patient group. 3-5 AF 
patients are treated with anticoagulants and other potent cardiovascular drugs. This may 
impose additional risks, such as bleeding and/or fainting,6, 7 especially to frail AF patients. 
 The CHA2DS2-VASc score has been designed and validated to specifically estimate 
the risk of stroke for patients with AF. 8 In some studies it has also proven to be predictive for 
mortality and bleeding in AF patients, as well as for death and major cardiovascular events in 
patient presenting to the emergency department with syncope. 9-11 Despite the fact that AF is 
the most common arrhythmia with a prevalence of 13-15% in patients over 75 years12 and in 
older people strongly associated with frailty,13 only limited data on frailty and its association 
with adverse outcome events in AF patients are available. 
 A recent review reported a prevalence of frailty in AF patients in sixteen studies, with 
a range from 6% in a registry of outpatients up to 100% in a nursing home population.14 This 
review reported an association between frailty and mortality, but also highlighted the lack of 
data on frailty and its association with other adverse outcomes in AF patients in a community 
setting. 
Therefore this study aimed to investigate the prevalence of frailty and the ability of a 
frailty index (FI) to predict adverse clinical outcomes in a large observational community 
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Methods 
Study design 
The Swiss Atrial Fibrillation Cohort Study (Swiss-AF) is an ongoing prospective, 
observational, multicenter cohort study across 14 centers in Switzerland. Detailed information 
on the study design has been published previously.15 The study complies with the Declaration 
of Helsinki, the study protocol has been approved by the local ethics committees, and 
informed written consent was obtained from each participant. 
Study population 
Overall, 2415 patients with documented AF were enrolled between 2014 and 2017. The pre-
specified inclusion criteria of the cohort study were a history of previously documented AF 
(documented by ECG or rhythm monitoring device within the last 60 months) and age ≥65 
years. In order to assess the socioeconomic aspects of AF in individuals who are part of the 
active workforce we enrolled additionally 10% of participants aged between 45 and 65 years. 
Patients with exclusively short, reversible form of AF (e.g. AF following cardiac surgery) 
were excluded. Of the 2415 patients 46 (1.9%) were excluded from this analysis; 30 (1.2%) 
due to study termination other than death before first follow-up visit, 7 (0.3%) due to not yet 
completed first follow-up and 9 (0.4%) due to missing/invalid date of the primary endpoint, 
resulting in a total number of 2369 (98.1%) patients remaining. 
Assessment of study variables 
Information about patient characteristics, risk-factors, comorbidities, physical activity, 
nutrition, current medications and medication adherence were collected by standardized case 
report forms and validated questionnaires. Cognitive assessment was evaluated by centrally 
trained study personnel using the Montreal Cognitive Assessment.16 Depressive symptoms 
were measured with the Geriatric Depression Scale.17 Health related quality of life was 
measured with the European Quality of life-5 Dimensions questionnaire (EQ-5D).18 The 
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 Body height and weight were directly measured using standardized devices and BMI 
was calculated. Blood pressure was measured three times in a supine position after at least 5 
minutes of rest using a validated device. A resting 16-lead electrocardiogram (ECG) of 5 
minutes duration was acquired in every study center. Atrial fibrillation type was classified 
according to the guidelines of the European Society of Cardiology into paroxysmal, persistent 
or permanent AF.6 The degree of peripheral edema and/or rales was assessed by local 
investigators. 
 Non-fasting venous blood samples were collected from each patient at baseline. The 
samples were stored at -80°C in a centralized biobank at the University Hospital Basel. 
Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD- EPI) equation.20 
Follow up assessments and clinical outcome events 
Yearly follow-up examinations were performed to update and re-assess all information and 
measures, and to collect information about adverse outcome events. Follow-up information 
was collected by local study personnel at each study center. If a clinical outcome event was 
reported by the patient or detected in available medical records, detailed information from the 
corresponding hospital and/or treating physicians was collected. All-cause death, stroke and 
bleeding were independently adjudicated by two physicians using a standardized form. In case 
of disagreement, a third physician reviewed the respective outcome event. 
 The primary outcome for this analysis was any unplanned hospitalization. Secondary 
outcomes included first cardiovascular hospitalization, first non-cardiovascular 
hospitalization, all-cause mortality, any bleeding, defined as major and clinically relevant 
non- major bleeding, and all stroke, defined as ischemic or hemorrhagic stroke. Detailed 
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Frailty index score 
Data of all variables included in the Frailty Index (FI) are provided in Table 1. Based on the 
available dataset the “deficit accumulation” approach was used. The FI was developed using 
40 unweighted variables, including symptoms, signs, diseases and disabilities.21 The variables 
were selected according to a standard procedure to create a frailty index score as described 
before.22 All variables were coded according to published or self-evident cut-offs and mapped 
to a 0-1 interval (indicating the occurrence and severity of a deficit). For each patient the FI 
score was calculated as the proportion of deficits present in relation to the number of deficits 
available. FI is a continuous variable scaled from 0-1 and was, similar to prior reports divided 
into the predefined levels non-frail (FI ≤0.1), pre-frail (FI >0.1 and <0.25) and frail (FI 
≥0.25).23 
Statistical analysis 
We used data up to October 1st, 2018 and included patients with at least one year of follow up. 
Baseline characteristics were stratified by frailty levels. Categorical variables are presented as 
counts (percentages) and compared using Chi-square tests. The distribution of continuous 
variables was analyzed using skewness, kurtosis and visual inspection of the histogram. 
Normally distributed continuous variables are presented as mean ± standard deviation (SD) 
and compared using ANOVA. Skewed variables are presented as median (interquartile range) 
and compared using the Kruskal-Wallis Rank Sum-test. 
 Person-years of follow-up were calculated from the date of study entry to the first 
occurrence of an outcome event, death, date of the last visit or lost-to-follow-up, whatever 
occurred first. To estimate the cumulative incidence of outcomes across frailty levels we used 
the cumulative incidence function. To assess the association between frailty and a clinical 
outcome event we constructed multivariable (cause-specific) Cox regression models to 
calculate hazard ratios (HR) (95% confidence intervals [95% CI]). Multivariable models were 
adjusted for age, sex, type of oral anticoagulation (i.e. vitamin K antagonist (VKA), direct 
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antiplatelets), type of AF, education and smoking. For relative risk calculations the group of 
non-frail patients was used as reference. We estimated the population-attributable risk (PAR) 
proportion of frailty and pre-frailty for each outcome event, using the formula pd x (HR-1/ 
HR), where pd is the proportion of frailty and pre-frailty among all patients with the outcome 
event and HR is the adjusted HR.24 A receiver operating characteristic curve was constructed 
to assess the area under the curve for the age- and sex adjusted FI and the CHA2DS2-VASc 
score for the prediction of stroke within one year, and for the other outcomes. The 
Spearmans`s correlation coefficient was conducted for the correlation between FI and 
CHA2DS2-VASc score. 
 Pre-specified subgroup analyses were performed for age (≥75y), sex, AF type and type 
of OAC. As a sensitivity analysis we recalculated the main models using Subdistribution 
Hazard regression as described by Fine and Gray, in order to take into account the competing 
risk of death.25 A p-value <0.05 was considered to indicate statistical significance. All 
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Results 
Baseline characteristics 
Baseline characteristics stratified by frailty level are presented in Table 2. Overall, mean 
(±SD) age was 73 (±8) years, 647 (27.3%) were female and 2141 (90.4%) were treated with 
OAC. Among participants, 28.7% were non-frail, 60.7% were pre-frail and 10.6% were frail. 
Frail patients were more likely to be older, current or past smokers and to have permanent AF. 
The mean CHA2DS2-VASc score was 2.1, 3.8 and 5.4 among non-frail, pre-frail and frail 
patients, respectively (p<0.001). Compared to non-frail and pre-frail patients, frail patients 
were more often treated with VKA (27.2%, 43.1% and 52%), but the overall frequency of 
OAC use did not differ across frailty levels. 
Outcomes 
During a median follow-up of 2.0 years, 762 of 2369 (32.2%) patients had one or more 
unplanned hospitalization for any cause. Of these first unplanned hospitalizations of any 
cause, 281 (36.9%) were cardiovascular and 481 (63.1%) were non-cardiovascular. 
 Overall, 322 (13.6%) patients had a first cardiovascular hospitalization and 523 
(22.1%) a first non-cardiovascular hospitalization, 50 (2.1%) a stroke, 273 (11.5%) a major 
bleeding or clinically relevant non- major bleeding and 159 (6.7%) died. The cumulative 
incidence of any unplanned hospitalization, all-cause mortality, stroke and bleeding stratified 
by frailty level are shown in Figure 1. 
Association of frailty level and unplanned hospitalizations 
The associations between frailty levels and unplanned hospitalization are presented in Table 
3. The overall incidence of any hospitalization was 19.8 per 100 patient-years, and it was 
10.6, 21.5 and 45.0 per 100 patient-years in non-frail, pre-frail and frail patients, respectively. 
Compared to non-frail patients, the multivariable adjusted HR for hospitalization in pre-frail 
and frail patients were 1.82 (95%CI 1.49-2.22) and 3.59 (95%CI 2.78-4.63), respectively. We 
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frailty. 
 Similar results were found for the association of pre-frailty and frailty with first 
cardiovascular hospitalization (adjusted HR 2.51, 95%CI 1.77-3.55; and adjusted HR 4.96, 
95%CI 3.28-7.49) and first non-cardiovascular hospitalization (adjusted HR 1.48, 95%CI 
1.17-1.87; and adjusted HR 2.67, 95%CI 1.97-3.62).  
Association of frailty level and secondary outcomes 
The overall incidence of all-cause mortality was 3.3 per 100 person-years, compared with 0.6, 
3.2 and 11.6 per 100 person-years in non-frail, pre-frail and frail patients, respectively. Pre-
frailty and frailty were significantly associated with all-cause mortality (adjusted HR 5.07, 
95%CI 2.43-10.59; and adjusted HR 16.72, 95%CI 7.75-36.05). Of all deaths we estimated 
that 81% could be attributable to pre-frailty or frailty (Table 4). 
 The incidence for stroke was 1.0 per 100 person-years overall, and 0.7, 1.0 and 2.3 for 
non-frail, pre-frail and frail patients. For bleeding, the overall incidence was 7.0 per 100 
person-years, and 3.7, 6.4 and 10.5 for non-frail, pre-frail and frail patients. Multivariable Cox 
regression for pre-frailty and frailty showed consistent results for bleeding (adjusted HR 1.53, 
95%CI 1.11-2.13; and adjusted HR 2.46, 95%CI 1.61-3.77), but not for stroke (adjusted HR 
1.43, 95%CI 0.67-3.06; and adjusted HR 3.29 95%CI 1.29-8.39). We estimated that 32% of 
all bleedings and 32% of all strokes could be attributable to pre-frailty or frailty (Table 4).  
Sensitivity and subgroup analyses 
Competing risk models for the main analyses revealed similar findings (Supplementary table 
2). Subgroup analyses for the association of frailty levels with any unplanned hospitalizations 
and the secondary outcomes showed consistent results, and none of the interaction terms were 
statistically significant (Supplementary table 3). Due to the small number of outcome events, 
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Receiver Operating Characteristic (ROC) curve of the age and sex adjusted FI and 
CHA2DS2-VASc score 
For the prediction of stroke after one year the age and sex adjusted FI performed comparably to 
the CHA2DS2-VASc score with an AUC of 0.657 (0.557–0.745) and 0.636 (0.516–0.742), 
respectively (Figure 2). For the other outcomes, for which the CHA2DS2-VASc score was not 
designed, the FI performed slightly better than the CHA2DS2-VASc score (Supplementary 
figure 1).The correlation coefficient between the FI and the CHA2DS2-VASc score was 
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Discussion 
Several findings emerged from this large community-based cohort study of AF patients. First, 
while the prevalence of frailty was low, almost two thirds of patients were pre-frail. Second, 
the majority of adverse outcomes was attributable to pre-frailty. These finding emphasize to 
carefully evaluate frail, and in particular pre-frail, patients. Third, the applied FI has proven to 
be a powerful tool to predict outcomes, with both pre-frailty and frailty being strongly 
associated with unplanned hospitalizations. Similar results were found for stroke, bleeding 
and death. Compared to the CHA2DS2-VASc score, the FI had a similar predictive power. 
Fifth, the prevalence of OAC did not differ among frailty groups, but frail patients were more 
likely to receive VKA. Further studies are needed to determine whether screening for frailty 
and targeted prevention strategies potentially reduce adverse outcomes and consecutive health 
related costs. 
 The prevalence of frailty among patients with AF was 10.6% and close to the lower 
bound of the previously reported range of 6% to 100% in a recent review.26 This may be 
explained by the stable condition of our patients compared to those in other studies, which 
included sicker and predominantly in-hospital patients, or patients from nursing homes. 
Another explanation could be the possible non-participation of frail patients. In addition, there 
are two different approaches to measure frailty (“phenotypic” vs. “deficit accumulation” 
frailty).21, 27 Furthermore the variable components of a given FI vary between studies. 
 Most patients in our study were pre-frail, accounting for the highest attributable risk 
for all adverse outcomes. Taking a public and economic health perspective, special attention 
should be given to this large pre-frail patient group. Multidisciplinary programs have been 
shown to be an effective strategy to increase the days alive and out of hospital in AF 
patients.28 In addition, multicomponent exercise interventions have been shown to reverse 
frailty. 29 Screening for frailty on a population basis is not yet recommended.30 But screening 
for frailty in AF patients together with a disease specific management, comprehensive 
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proactive approach to a population with a high percentage of pre-frailty and frailty. However, 
whether screening for frailty and targeted prevention strategies for pre-frail and frail AF 
patients improve outcomes needs to be shown in future studies. 
 We observed that >40% of any unplanned hospitalizations were attributable to pre-
frailty and frailty (Take home figure). Nguyen and colleagues showed in a small cohort of in-
hospital AF patients no association between frailty and re-hospitalization.32 Further 
comparisons are difficult due to the lack of data addressing the association of frailty and 
unplanned hospitalizations in AF patients. It might appear unexpected that the rate for 
unplanned hospitalizations was higher for non-cardiovascular than cardiovascular reasons. 
Partly, this is explained by the older age and higher comorbidity burden in the frail group. 
Other explanations might be compromised immune response, accounting for more infections 
and cancer in frail patients33, 34 and the higher comorbidity-rate in AF patients leading to a 
higher risk of non-cardiovascular disease in general. Unfortunately, we were not able to 
further clarify the exact reasons for hospitalizations. To identify modifiable risk factors and 
possibly preventable reasons for hospitalizations in pre-frail and frail AF patients further 
studies are needed. 
 We also found a strong association between frailty and stroke, bleeding and all-cause 
mortality, which is consistent with previous findings.32, 35 The low incidence of stroke in our 
cohort may be explained by the high prevalence of oral anticoagulation. Nevertheless, after 
multivariable adjustment (including type of OAC) frailty remained an independent predictor 
of stroke. Compared to the CHA2DS2-VASc score, the FI had a similar predictive power in 
this study of AF patients for the prediction of unplanned hospitalization, stroke, bleeding and 
death, with a strong correlation. When interpreting these results one should note that a simple 
clinical risk score such as the CHA2DS2-VASc score not validated for frailty performs 
comparably to our 40-item frailty score. 
 While the CHA2DS2-VASc score was highest in frail patients, the prevalence of OAC 
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prevalence is in line with other studies assessing the prescription of OAC in AF patients in 
Europe at the time of our study. 36 Although DOACs with their better risk/benefit ratio seem 
preferable in frail patients,37 in our study frail patients were more likely to receive VKA. This 
finding may partly be explained by a physician preference for close INR monitoring, 
especially in elderly or frail AF patients. 38 A study from the U.S. found, that DOACs were 
less likely prescribed to elderly patients with an increased risk for stroke and bleeding, and to 
those with more comorbidities. 39 However, the higher rate of renal dysfunction in frail 
patients cannot explain this observation alone. Another explanation may be the time period of 
patient enrollment to our study (2014-2017), since the first DOAC in Switzerland for 
prevention of stroke in AF was approved 2012. A study in Swiss AF patients found an 
increase of DOAC use between 2010 and 2015, but most patients stayed on their initial 
therapy with VKA. 40 As expected the bleeding risk seemed to be higher on OAC in all frailty 
groups. But there were no significant differences in bleeding risk with regard to the type of 
OAC, may be due to the small number of events in the subgroups. To clarify the question 
about OAC in frail AF patients, more clinical trials in this particular population are needed. 
 Our study has the advantage of being a large community-based cohort of well-
characterized patients with a very low rate of missing values, which enabled us to build a 
strong FI. Also, the clinical outcomes were collected accurately and validated by independent 
experts. However, some potential limitations need to be considered. First, being an 
observational study, we cannot confirm causality, and residual confounding may persist 
despite comprehensive multivariable adjustment. Second, we used only a single measurement 
of frailty at study entry, which is associated with some risk of misclassification. Nevertheless, 
our results and those of others have shown, that a FI based on random composites of deficits 
is a robust model and capable to appropriately predict outcomes.41 Third, study patients were 
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Conclusions 
In this large cohort of elderly AF patients, the FI was a powerful tool to predict unplanned 
hospitalizations and other adverse outcomes. The risk of unplanned hospitalization was 
highest among frail patients, but pre-frail patients accounted for the largest proportion of total 
number of hospitalizations, a finding that emphasizes the clinical need to carefully evaluate 
these patients. To determine whether screening and specific interventions for pre-frail and 
frail AF patients can potentially reduce adverse outcomes and its socio-economic 
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Figure legends 
Figure 1. Cumulative incidence of clinical outcomes stratified by levels of frailty 
Cumulative incidence of unplanned hospitalization s (a), all- cause mortality (b), bleeding (c) 
and stroke (d) stratified by frailty level.  
 
Figure 2. Receiver Operating Characteristic (ROC) curve of the adjusted FI and 
CHA2DS2-VASc score for stroke 
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Table 1. Variables of the Frailty Index Score stratified by level of frailty 
    Stratified by frailty level 
  Overall non-frail pre-frail frail 
n 2369 (100) 681 (28.7) 1436 (60.7) 252 (10.6) 
Physical activity (Yes/No) 1095 (46.3)  495 (72.9)  562 (39.2)  38 (15.1)  
History of myocardial infarction 385 (16.3) 22 (3.2) 267 (18.6) 96 (38.1) 
History of PTCA/ Stent 561 (23.7) 45 (6.6) 397 (27.6) 119 (47.2) 
History of Stroke / TIA 473 (20.0)  67 (9.8)  312 (21.8)  94 (37.3)  
History of systemic embolism 125 (5.3)  11 (1.6)  84 (5.9)  30 (11.9)  
History of congestive heart failure 613 (25.9)  38 (5.6)  413 (28.8)  162 (64.3)  
History of hypertension 1642 (69.3)  288 (42.3)  1123 (78.2)  231 (91.7)  
History of diabetes mellitus 403 (17.0)  10 (1.5)  268 (18.7)  125 (49.6)  
History of peripheral vasclular disease 190 (8.0)  7 (1.0)  112 (7.8)  71 (28.2)  
History of chronic kidney disease 498 (21.0)  16 (2.4)  336 (23.4)  146 (57.9)  
History of thyroid disease 343 (14.5)  50 (7.3)  224 (15.6)  69 (27.4)  
History of malignacy 378 (16.0)  55 (8.1)  247 (17.2)  76 (30.2)  
History of major bleeding 149 (6.3)  12 (1.8)  92 (6.4)  45 (17.9)  
History of minor bleeding 253 (10.7)  23 (3.4)  168 (11.7)  62 (24.6)  
History of gastric ulcera 106 (4.5)  9 (1.3)  57 (4.0)  40 (15.9)  
Recurrent falls 198 (8.4)  9 (1.3)  115 (8.0)  74 (29.4)  
Other medical problems 639 (27.0)  107 (15.7)  422 (29.4)  110 (43.7)  
Edema 494 (20.9)  34 (5.0)  341 (23.8)  119 (47.2)  
Rales 75 (3.2)  3 (0.4)  43 (3.0)  29 (11.5)  
Body mass index 28.0 ± 4.8 26.5 ± 3.8 28.0 ± 4.9 29.0 ± 5.5 
Systolic blood pressure 134 ± 18.7 131 ± 15.4 135 ± 19.4 134 ± 22.0 
Doing usual activity (EQ- 5D)               
   unable 20 (0.8)  0 (0.0)  8 (0.6)  12 (4.8)  
   some problems 324 (13.7)  13 (1.9)  192 (13.4)  119 (47.2)  
   no problems 2024 (85.4)  667 (97.9)  1236 (86.1)  121 (48.0)  
Having pain or other physical issues (EQ- 5D)             
   a lot of pain 60 (2.5)  1 (0.1)  35 (2.4)  24 (9.5)  
   some pain 1023 (43.2)  176 (25.8)  679 (47.3)  168 (66.7)  
   no pain 1283 (54.2)  503 (73.9)  721 (50.2)  59 (23.4)  
Feeling worried, sad or unhappy (EQ- 5D)    
 
       
   very 15 (0.6)  2 (0.3)  8 (0.6)  5 (2.0)  
   a bit 453 (19.1)  80 (11.7)  285 (19.8)  88 (34.9)  
   not 1900 (80.2)  598 (87.8)  1143 (79.6)  159 (63.1)  
Self-rated health 72 ± 17.5 82 ± 11.6 71 ± 16.9 56 ± 18.8 
Orienation (Part of MoCA)               
   0 1 (0.0)  0 (0.0)  1 (0.1)  0 (0.0)  
   1 0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)  
   2 3 (0.1)  0 (0.0)  0 (0.0)  3 (1.2)  
   3 4 (0.2)  1 (0.1)  3 (0.2)  0 (0.0)  
   4 17 (0.7)  2 (0.3)  10 (0.7)  5 (2.0)  
   5 144 (6.1)  25 (3.7)  90 (6.3)  29 (11.5)  
   6 2198 (92.8)  652 (95.7)  1331 (92.8)  215 (85.3)  
Mathematical performance (Part of MoCA)              
   0 19 (0.8)  1 (0.1)  12 (0.8)  6 (2.4)  
   1 44 (1.9)  7 (1.0)  29 (2.0)  8 (3.2)  
   2 175 (7.4)  32 (4.7)  109 (7.6)  34 (13.5)  
   3 2127 (89.8)  639 (93.8)  1285 (89.5)  203 (80.6)  
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   0 304 (12.8)  39 (5.7)  204 (14.2)  61 (24.2)  
   1 184 (7.8)  30 (4.4)  130 (9.1)  24 (9.5)  
   2 372 (15.7)  82 (12.0)  237 (16.5)  53 (21.0)  
   3 501 (21.2)  137 (20.1)  317 (22.1)  47 (18.7)  
   4 541 (22.8)  188 (27.6)  316 (22.0)  37 (14.7)  
   5 463 (19.6)  202 (29.7)  231 (16.1)  30 (11.9)  
Verbal fluency (Part of MoCA) 10 ± 4.0 12 ± 4.0 9 ± 3.8 8 ± 3.2 
Depression (GDS) 1 (1.9) 1 (1.4) 2 (1.9) 3 (2.6) 
Feeding (Barthel- Index) 
    
   unable 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
   needs help 8 (0.3)  0 (0.0)  3 (0.2)  5 (2.0)  
   Independent 2359 (99.7) 679 (100) 1433 (99.8) 247 (98.0) 
Personal grooming (Barthel- Index) 
    
   needs help 12 (0.5) 1 (0.1) 1 (0.1) 10 (4.0) 
   independent 2357 (99.5)  680 (100.0)  1435 (99.9)  242 (96.0)  
Bathing (Barthel- Index) 
    
   needs help 48 (2.0) 0 8 (0.6) 40 (15.9) 
   independent 2321 (98.0)  681 (100.0)  1428 (99.4)  212 (84.1)  
Dressing (Barthel- Index)               
   dependent 1 (0.0)  0 (0.0)  0 (0.0)  1 (0.4)  
   needs help 33 (1.4)  0 (0.0)  6 (0.4)  27 (10.7)  
   independent 2335 (98.6)  681 (100.0)  1430 (99.6)  224 (88.9)  
Toilet use (Barthel- Index)    
 
       
   dependent 0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)  
   needs help 12 (0.5)  0 (0.0)  5 (0.3)  7 (2.8)  
   independent 2357 (99.5)  681 (100.0)  1431 (99.7)  245 (97.2)  
Urinary continence (Barthel- Index)    
 
       
   incontinent 29 (1.2)  0 (0.0)  15 (1.0)  14 (5.6)  
   occasional accident 183 (7.7)  21 (3.1)  121 (8.4)  41 (16.3)  
   continent 2157 (91.1)  660 (96.9)  1300 (90.5)  197 (78.2)  
Bowel continence (Barthel- Index)               
   incontinent 7 (0.3)  0 (0.0)  3 (0.2)  4 (1.6)  
   occasional accident 51 (2.2)  1 (0.1)  36 (2.5)  14 (5.6)  
   continent 2311 (97.6)  680 (99.9)  1397 (97.3)  234 (92.9)  
Transfer (Barthel- Index)               
   unable 0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)  
   major help 3 (0.1)  0 (0.0)  2 (0.1)  1 (0.4)  
   minor help 31 (1.3)  0 (0.0)  11 (0.8)  20 (7.9)  
   independent 2334 (98.6)  680 (100.0)  1423 (99.1)  231 (91.7)  
Mobility (Barthel- Index)               
   immobile 1 (0.0)  0 (0.0)  1 (0.1)  0 (0.0)  
   wheelchair independent 7 (0.3)  0 (0.0)  1 (0.1)  6 (2.4)  
   walks with help of one person 68 (2.9)  0 (0.0)  23 (1.6)  45 (17.9)  
   independent (but may use any aid) 2293 (96.8)  681 (100.0)  1411 (98.3)  201 (79.8)  
Stairs (Barthel- Index)    
 
       
   unable 17 (0.7)  1 (0.1)  3 (0.2)  13 (5.2)  
   needs help 61 (2.6)  0 (0.0)  26 (1.8)  35 (13.9)  
   independent 2291 (96.7)  680 (99.9)  1407 (98.0)  204 (81.0)  
Data are presented as mean ± standard deviation, or median (interquartile range), or number (percentage) 
Levels of frailty: frail (frailty index ≥ 0.25), pre- frail (frailty index <0.25 and >0.1), non- frail (frailty index ≤ 0.1) 
Missing values: Physical activity n = 3, History of Stroke/TIA n = 2, History of congestive heart failure n = 2, History of chronic 
kidney disease n = 2, History of minor bleeding n = 2, Edema n = 3, Rales n = 3, Systolic blood pressure n = 16, Diastolic blood 
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Table 2. Baseline characteristics (not part of the Frailty Index Score) stratified by frailty level 
    Stratified by frailty level   
  Overall non-frail pre-frail frail p- value 
n (%) 2369 (100) 681 (28.7) 1436 (60.7) 252 (10.6) 
 
Age, years 73 ± 8 69 ± 8 75 ± 8 77 ± 7 <0.001 
Female Sex 647 (27.3)  163 (23.9)  412 (28.7)  72 (28.6)  0.06 
Smoking 
    
<0.001 
   Current 172 (7.3)  41 (6.0)  104 (7.2)  27 (10.7)  
 
   Past 1157 (48.8)  301 (44.2)  717 (49.9)  139 (55.2)  
 
   Never  1040 (43.9)  339 (49.8) 615 (42.8)  86 (34.1)  
 
CHA2DS2-VASc Score 3.5 ± 1.7 2.1 ±1.3 3.8 ± 1.4 5.4 ± 1.3 <0.001 
Atrial fibrillation- Type 
    
<0.001 
   Paroxysmal 1062 (44.8)  357 (52.4)  608 (42.3)  97 (38.5)  
 
   Persistent 694 (29.3)  217 (31.9)  421 (29.3)  56 (22.2)  
 
   Permanent 613 (25.9)  107 (15.7)  407 (28.3)  99 (39.3)  
 
 Type of oral anticoagulation 
    
<0.001 
   VKA 936 (39.5)  186 (27.2)  619 (43.1)  131 (52.0)  
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   No OAC 228 (9.6) 79 (11.6) 119 (8.3) 30 (11.9)  
Aspirin 399 (16.8)  52 (7.6)  278 (19.4)  69 (27.4)  <0.001 
Other antiplatelet therapy 147 (6.2)  16 (2.4)  109 (7.6)  22 (8.7)  <0.001 
Dual antiplatelet therapy 76 (3.2) 8 (1.2) 54 (3.8) 14 (5.6) 0.001 
eGFR <30ml/min/1.73m2 (CKD- EPI) 144 (6.2) 3 (0.4) 98 (7.0) 43 (17.6) <0.001 
Data are presented as mean ± standard deviation , or numbers (percentage); estimated glomerular filtration rate (eGFR) 
Levels of frailty: frail (frailty index ≥ 0.25), pre- frail (frailty index <0.25 and >0.1), non- frail (frailty index ≤ 0.1) 
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Table 3. Cox Regression for the Association between frailty and unplanned hospitalizations 










HR (95% CI) 
unadjusted 
p-value 
HR (95% CI) 
adjusted 
p-value 
 Any unplanned hospitalization 




pre- frail 488 / 1436 2267 21.5 0.29 2.00 (1.65 - 2.42) <0.001 1.82 (1.49 - 2.22) <0.001 
frail 139 / 252 309 45.0 0.13 4.10 (3.23 - 5.19) <0.001 3.59 (2.78 - 4.63) <0.001 
 First cardiovascular hospitalization 
non- frail 41 / 681 1393 3.0  Ref.  Ref.  
pre- frail 213 / 1436 2630 8.1 0.40 2.70 (1.93 - 3.77) <0.001 2.51 (1.77 - 3.55) <0.001 
frail 68 / 252 409 16.6 0.17 5.44 (3.69 - 8.02) <0.001 4.96 (3.28 - 7.49) <0.001 
 First non-cardiovascular hospitalization 
non- frail 103 / 681 1333 7.7  Ref.  Ref.  
pre- frail 329 / 1436 2512 13.1 0.20 1.70 (1.36 - 2.12) <0.001 1.48 (1.17 - 1.87) 0.001 
frail 91 / 252 363 25.1 0.11 3.24 (2.45 - 4.30) <0.001 2.67 (1.97 - 3.62) <0.001 
Data are presented as Hazard ratio (HR) with 95% confidence intervals (CI), reference value is non- frail (frailty index ≤ 0.1) 
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Table 4. Cox Regression for the association between frailty and all-cause mortality, all stroke and any bleeding 










HR (95% CI) 
unadjusted 
p-value 
HR (95% CI) 
adjusted 
p-value 
 All-cause mortality 




pre- frail 95 / 1436 2931 3.2 0.48 5.98 (2.91 - 12.31) <0.001 5.07 (2.43 - 10.59) <0.001 
frail 56 / 252 484 11.6 0.33 21.51 (10.25 - 45.14) <0.001 16.72 (7.75 - 36.05) <0.001 
 Stroke  




pre- frail 29 / 1436 2904 1.0 0.17 1.47 (0.72 - 3.02) 0.3 1.43 (0.67 - 3.06) 0.35 
frail 11 / 252 476 2.3 0.15 3.48 (1.48 - 8.20) 0.004 3.29 (1.29 - 8.39) 0.01 
 Bleeding  




pre- frail 175 / 1436 2730 6.4 0.22 1.71 (1.26 - 2.34) <0.001 1.53 (1.11 - 2.13) 0.01 
frail 46 / 252 438 10.5 0.10 2.82 (1.90 - 4.20) <0.001 2.46 (1.61 - 3.77) <0.001 
Data are presented as Hazard ratio (HR) with 95% confidence intervals (CI), reference value is non- frail (frailty index ≤ 0.1) 
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